Market Intelligence, Clinical Progress, and High-Purity Reagents for Endosomal Trafficking and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TOM1L2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TOM1L2 Recombinant Protein (VHS-GAT Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biophysical binding assays. |
View TOM1L2 Products |
| Gene Delivery | TOM1L2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and intracellular trafficking assays. |
View TOM1L2 Products |
| Benchmark Ab | Anti-TOM1L2 Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, IP, and IHC. |
View TOM1L2 Products |
| Validator | TOM1L2 siRNA Set Target-specific knockdown pool for functional validation of endosomal cargo degradation. |
View TOM1L2 Products |
| Related Target A | TOLLIP Direct binding partner of TOM1L2; essential co-factor in ubiquitin-dependent cargo sorting. |
View TOLLIP Products |
| Related Target B | EGFR Key receptor cargo whose endosomal trafficking and degradation are regulated by TOM1L2. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | Lentiviral transduction systems optimized for high-efficiency expression in hard-to-transfect cell lines. |
| Domain-Specific Interaction Screening | Truncated VHS or GAT domain recombinant proteins designed with precise boundary verification for SPR/MST. |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies and validated siRNA pools included. |
| Batch-to-Batch Inconsistency | Strict mass spectrometry and chromatography quality control ensuring >95% purity and correct theoretical MW. |
Live TOM1L2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TOM1L2 therapeutics is intensifying, with major players shifting focus from traditional global signaling inhibition to modulating intracellular trafficking pathways. As first-generation endosomal pathway targets reach the clinic, the next wave of R&D is targeting TOM1L2 to overcome receptor tyrosine kinase (RTK) recycling-mediated drug resistance.
TOM1L2 (Target of Myb1-like protein 2) functions as a critical adapter in the multivesicular body (MVB) sorting pathway. By interacting with clathrin, TOLLIP, and ubiquitinated cargo, it dictates the degradation kinetics of signaling receptors like EGFR and ERBB2. Dysregulation of TOM1L2-mediated trafficking has been increasingly implicated in solid tumors and neurodegenerative disorders, making it a highly sought-after target for proximity-inducing therapies (PROTACs/LYTACs) and small-molecule protein-protein interaction (PPI) inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Institutes, Biotech Startups | EGFR-mutant NSCLC, Breast Cancer | High-purity VHS/GAT domain proteins for binding kinetics (SPR/MST). |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Developers | Oncology, Neurodegeneration | Stable cell lines expressing tagged TOM1L2 via Lentivirus for degradation kinetics assays. |
| RNA Therapeutics / siRNA | Oligonucleotide Therapeutics Biopharma | Inflammatory Diseases, Rare Disorders | Validated siRNA sets for off-target and knockdown efficiency validation. |